Abbott said it will close its $23 billion acquisition of Exact Sciences after receiving all regulatory clearances, a deal that expands Abbott’s presence in oncology diagnostics. Exact shareholders approved the transaction and Abbott completed financing to fund the purchase. The acquisition brings Cologuard, Oncotype DX, Oncodetect MRD testing and multi‑cancer detection assets into Abbott’s diagnostics portfolio. Abbott expects the deal to add roughly $3 billion in incremental sales in 2026 and to expand its capabilities in one of healthcare’s fastest‑growing areas. The move accelerates consolidation in diagnostics as large medical‑device companies seek to embed molecular testing into clinical workflows.